The human DEK oncogene stimulates Β-catenin signaling, invasion and mammosphere formation in breast cancer

Oncogene

Volumn 30, Issue 24, 2011, Pages 2741-2752

  Privette Vinnedge, L M ^a   McClaine, R ^b   Wagh, P K ^b   Wikenheiser Brokamp, K A ^a   Waltz, S E ^b   Wells, S I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

b catenin; breast cancer; cancer stem cells; DEK; metastasis

Indexed keywords

BETA CATENIN; PEPTIDES AND PROTEINS; PROTEIN DEK; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS; PROTO-ONCOGENES; SIGNAL TRANSDUCTION;

EID: 79958837212     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.2     Document Type: Article

References (52)

1. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI et al. (2007). Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 5: 881-890. (Pubitemid 47416665)
2. ACS, Breast Cancer Facts & Figures 2009-2010. American Cancer Society, Inc.: Atlanta, 2009.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988. (Pubitemid 36418143)
4. Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C. (2000). The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 14: 1308-1312. (Pubitemid 30397074)
5. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ et al. (2006). Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169: 233-246.
6. Andreassen PR, Margolis RL. (1994). Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol 127: 789-802.
7. Bosco EE, Knudsen ES. (2007). RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle 6: 667-671. (Pubitemid 46535677)
8. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB et al. (2007). Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 46: 118-129. (Pubitemid 44913377)
9. Campillos M, Garcia MA, Valdivieso F, Vazquez J. (2003). Transcriptional activation by AP-2alpha is modulated by the oncogene DEK. Nucleic Acids Res 31: 1571-1575. (Pubitemid 36304919)
10. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M et al. (2006). DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5: 1202-1207. (Pubitemid 43845381)
11. Dignam JD, Lebovitz RM, Roeder RG. (1983). Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489.
12. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. (2003). In vitro propagation and transcrip-tional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. (Pubitemid 36583168)
13. Dontu G, Liu S, Wicha MS. (2005). Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev 1: 207-213.
14. Euhus DM, Hudd C, LaRegina MC, Johnson FE. (1986). Tumor measurement in the nude mouse. J Surg Oncol 31: 229-234. (Pubitemid 16104025)
15. Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J et al. (2004). Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol 164: 285-293. (Pubitemid 38364612)
16. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806. (Pubitemid 26134320)
17. Guarino M, Rubino B, Ballabio G. (2007). The role of epithelial- mesenchymal transition in cancer pathology. Pathology 39: 305-318. (Pubitemid 46897605)
18. Heuberger J, Birchmeier W. (2010). Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol 2: a002915.
19. Johung K, Goodwin EC, DiMaio D. (2007). Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J Virol 81: 2102-2116.
20. Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C. (2001). Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 276: 26317-26323.
21. Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N et al. (2008). DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 28: 3245-3257. (Pubitemid 351657089)
22. Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS et al. (2009). Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 69: 6405-6413.
23. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S et al. (1999). Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59: 4990-4996. (Pubitemid 29472905)
24. Le Hir H, Gatfield D, Izaurralde E, Moore MJ. (2001). The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. Embo J 20: 4987-4997. (Pubitemid 32848650)
25. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X et al. (2003). Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100: 15853-15858. (Pubitemid 38021079)
26. Lu ZL, Luo DZ, Wen JM. (2005). Expression and significance of tumor-related genes in HCC. World J Gastroenterol 11: 3850-3854.
27. McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E et al. (2000). The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 150: 309-320. (Pubitemid 30491355)
28. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555. (Pubitemid 41420886)
29. Prahalad P, Calvo I, Waechter H, Matthews JB, Zuk A, Matlin KS. (2004). Regulation of MDCK cell-substratum adhesion by RhoA and myosin light chain kinase after ATP depletion. Am J Physiol Cell Physiol 286: C693-C707. (Pubitemid 38292676)
30. Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. (2007). Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res 67: 6064-6074. (Pubitemid 47037485)
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. (Pubitemid 38391943)
32. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S. (2003). The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 127: 336-340. (Pubitemid 36382893)
33. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132. (Pubitemid 43202662)
34. Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP. (2006). Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 281: 26802-26812. (Pubitemid 44401709)
35. Schmittgen TD, Livak KJ. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108. (Pubitemid 351818697)
36. Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K et al. (2010). DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 29: 4671-4681.
37. 0 splice site recognition by DEK. Science 312: 1961-1965. (Pubitemid 43993724)
38. Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM et al. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086. (Pubitemid 20331424)
39. Tomayko MM, Reynolds CP. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154. (Pubitemid 19163397)
40. Tubiana M, Koscielny S. (1999). The rationale for early diagnosis of cancer-the example of breast cancer. Acta Oncol 38: 295-303. (Pubitemid 29278926)
41. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al(2002), Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536. (Pubitemid 34130608)
42. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. (Pubitemid 35461656)
43. Waldmann T, Baack M, Richter N, Gruss C. (2003). Structure-specific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 31: 7003-7010. (Pubitemid 37508807)
44. Waldmann T, Eckerich C, Baack M, Gruss C. (2002). The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 277: 24988-24994. (Pubitemid 34951801)
45. Waldmann T, Scholten I, Kappes F, Hu HG, Knippers R. (2004). The DEK protein-an abundant and ubiquitous constituent of mammalian chromatin. Gene 343: 1-9. (Pubitemid 39551025)
46. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679. (Pubitemid 40260888)
47. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. (2006). Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 26: 7506-7519. (Pubitemid 44547701)
48. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K et al. (2005). The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 79: 14309-14317. (Pubitemid 41552728)
49. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA et al. (2009a). Over-expression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 69: 1792-1799.
50. Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ et al. (2009b). DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 174: 71-81.
51. Woodward WA, Chen MS, Behbod F, Rosen JM. (2005). On mammary stem cells. J Cell Sci 118: 3585-3594. (Pubitemid 41309406)
52. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. (2008). Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 68: 4674-4682.